See Seres Therapeutics's analyst price targets ($12) vs the current share price.
Get informed when a big investor buys or sells
+ Follow$3.52
1 analysts in the last 4 months
High: $12 | Low: $12
No recommendations in the last 4 months.
Seres Therapeutics posts a target price of $12. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
A target price of $12 for MCRB means covering analysts, on average, see the stock 240.9% upside of $3.52 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.
Context for MCRB's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Seres Therapeutics's other metric pages and overview cover the third.
Judging Seres Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $12 here, then scan peer and history charts to see if the gap is persistent.